Cellular localization of p-tau217 in brain and its association with p-tau217 plasma levels
Acta Neuropathologica Communications volume 10, Article number: 3 (2022)
Recent studies highlight phosphorylated tau (p-tau) at threonine tau 217 (p-tau217) as a new promising plasma biomarker for pathological changes implicated in Alzheimer’s disease (AD), but the specific brain pathological events related to the alteration in p-tau217 plasma levels are still largely unknown. Using immunostaining techniques of postmortem AD brain tissue, we show that p-tau217 is found in neurofibrillary tangles (NFTs) and neuropil threads that are also positive for p-tau181, 202, 202/205, 231, and 369/404. The p-tau217, but not the other five p-tau variants, was also prominently seen in vesicles structure positive for markers of granulovacuolar degeneration bodies and multi-vesicular bodies. Further, individuals with a high likelihood of AD showed significantly higher p-tau217 area fraction in 4 different brain areas (entorhinal cortex, inferior temporal gyrus, and superior frontal gyrus) compared to those with Primary age related tauopathy or other non-AD tauopathies. The p-tau217 area fraction correlated strongly with total amyloid-beta (Aβ) and NFT brain load when the whole group was analyzed. Finally, the mean p-tau217 area fraction correlated significantly with p-tau217 concentrations in antemortem collected plasma specifically in individuals with amyloid plaques and not in those without amyloid plaques. These studies highlight differences in cellular localization of different p-tau variants and suggest that plasma levels of p-tau217 reflect an accumulation of p-tau217 in presence of Aβ plaque load.
Tau is a microtubule-associated protein crucial for the stabilization of the neuronal cytoskeleton. Mis-localization, aggregation, and hyperphosphorylation of the protein are thought to lead to pathological tau spread and neuronal death. This scenario occurs in several different neurodegenerative disorders and aggregated phosphorylated tau (p-tau), forming neurofibrillary tangles (NFT) and neuropil threads (NT), constitutes one of the major neuropathological hallmarks of Alzheimer’s disease (AD). Importantly, phosphorylation of tau can occur at several different sites and give rise to different p-tau variants [5, 25]. Many of these variants can be detected in cerebrospinal fluid (CSF) . The p-tau181 variant is the most studied p-tau biomarker and is today, together with total tau and amyloid-beta (Aβ) 42, used in clinical practice as a biomarker to detect AD pathology in patients with cognitive symptoms . However, collecting CSF involves invasive lumbar puncture and thus much effort has been put into finding blood biomarkers for AD. Indeed, advances in the identification and validation of plasma biomarkers have recently led to several promising findings . One of those findings involves the tau variant phosphorylated at Thr217 (p-tau217) . Plasma levels of p-tau217 have been shown to associate with brain tau pathology specifically found in the presence of Aβ plaques in postmortem tissue [16, 19], which is in agreement with imaging studies demonstrating correlations between plasma p-tau217 and tau- positron emission tomography (PET) in patients with AD, but not in non-AD tauopathies [10, 19, 22]. Even more intriguing are reports showing differences in plasma p-tau isoforms in their correlation with tau PET or diagnostic accuracy. These findings indicate that the phosphorylation of tau at Thr217 might be related to a subtle and unique aspect of pathology that is different from the other isoforms.What drives this rise in plasma p-tau217 in AD and its underlying cellular pathological mechanism remains to be investigated. In the current study, we initiate such an investigation by exploring the cellular localization of p-tau217, in comparison to five other p-tau variants (p-tau181, 231, 202, 202/205, and 369/404), in the Cornu Ammonis 1 (CA1) of the hippocampus of AD patients. We also analyzed the presence of p-tau217 in 4 different brain areas (CA1, entorhinal cortex (EC) inferior temporal cortex (ITG), and superior frontal cortex (SFG)) of neuropathologically diagnosed individuals. Finally, we determined whether the p-tau217 load in these brain areas correlates with p-tau217 concentrations in antemortem collected plasma.
Material and methods
Individuals included in the study: Cohort 1 and Cohort 2
Samples from two cohorts (Cohort 1 and 2) were analyzed in the study. The samples included postmortem collected brain samples containing CA1, EC (Cohort 1 and 2), ITG and SFG (Cohort 2), and plasma collected near the end of life (Cohort 2). Cohort 1 (n = 23) consisted of donors from the Netherlands Brain Bank (NBB), and included non‐demented controls (NC; n = 12) and clinically diagnosed AD patients (n = 11). The demographics of the 2 groups are shown in Table 1. The presence of NFT and NT (visualized by AT8 staining) in this cohort were scored according to Braak stages I-VI  and the Aβ plaques (visualized by BETA-A4 staining) were scored into O, A, B, C, where O = zero, A = some, B = moderate and C = many . Cohort 2 included (n = 44) participants from an antemortem-postmortem study, the Arizona Study of Aging and Neurodegenerative Disorders and Brain and Body Donation Program at Banner Sun Health Research Insititute . The cohort was scored according to National Institute on Aging and Reagan Institute (NIA-RI) criteria , based on NFT Braak stages (I-VI)  and Consortium to Establish a Registry for Alzheimer Disease (CERAD) neuritic Aβ-plaque scores  as described earlier [16, 19]. The cohort consisted of (n = 12) individuals with Primary age related tauopathy (PART) (Braak III-IV, zero-sparse neuritic plaques), (n = 5) patients with either progressive supranuclear palsy (PSP) (n = 3) or corticobasal degeneration (CBD) (n = 2) (Braak III-IV, zero neuritic plaques meeting neuropathological criteria for CBD or PSP) (called Non-AD tauopathy), (n = 16) individuals with an intermediate likelihood of Alzheimer’s disease (Braak stage III-IV, moderate-frequent neuritic plaques) (called intermediate AD) and (n = 11) individuals with high likelihood of Alzheimer’s disease (Braak stage V-VI, frequent neuritic Aβ-plaque) (called high AD). Demographics of the 4 groups are shown in Table 2. Procedures for the collection of plasma and brain tissue from Cohort 2 have been described earlier [16, 19]. In addition, Aβ plaque and NFT/NT (visualized by Campbell-Switzer and Gallyas silver staining, respectively) load in the entorhinal cortex, hippocampus, temporal lobe, parietal lobe, and frontal lobe of Cohort 2 was scored (0–3 per region) and summarized as total plaque load and NFT/NT load (0–15) (for detailed procedures see ). Informed consent for the use of brain tissue, plasma, and clinical data for research purposes was obtained from all subjects or their legal representatives in accordance with the International Declaration of Helsinki .
Brain sample preparation
The brain samples were post‐fixed in paraformaldehyde (PFA) (4%) for either 14–20 h (Cohort 1) or 36–72 h (Cohort 2) directly after autopsy and thereafter incubated in either phosphate-buffered saline (PBS) with 30% sucrose (Cohort 1) or in 2% dimethyl sulfoxide/20% glycerol (Cohort 2). The tissue was then sectioned in 40 μm free-floating sections and stored in cryoprotectant at − 20 °C (Cohort 1) or at room temperature (Cohort 2) until used for immunostaining.
For analysis of the cellular localization of p-tau217, hippocampal sections from AD patients in Cohort 1 were stained with antibodies directed against p-tau217 together with antibodies against p-tau 181, 231, 202/205, 202, 369/404, CD63, and Ckid (clones, source, and species shown in Table 3) as well as together with the thiophene-based ligand p-FTAA (a ligand that binds to aggregated tau and has been shown to co-label neurons immunostained for AT8 ). The sections were incubated for 1 h with blocking solution (BS) containing 5% goat serum (Jackson Immunoresearch) and 0.25% Triton in KPBS and then incubated with primary antibodies in BS overnight (ON) at 4 °C. The next day the sections were washed and incubated with secondary antibodies (Dylight 546 goat-anti-rabbit and Alexa 488 goat-anti-mouse (Thermo Fischer Scientific)) in BS ON at 4 °C. Double staining against p-tau217 and tau, p-tau231, GFAP (astrocyte marker), or iba-1 (microglia marker) was performed in a sequential manner, where the staining against p-tau 231, GFAP, and Iba-1 staining was performed first, followed by an incubated ON at 4 °C with a biotinylated version of the p-tau217 antibody in BS. Next day the sections were incubated in streptavidin 549 (Thermo Fischer Scientific) for 2 h. The staining against p-tau217 together with the bioligands p-FTAA was also performed sequentially, where p-tau217 was stained first followed by an incubation with p-FTAA in KPBS for 1 h in room temperature (RT). All stained sections were incubated in Sudan Black (1% in 70% ethanol) (Sigma-Aldrich) for 5 min before they were mounted with Vectashield Set mounting medium containing DAPI (Vector Laboratories). Associations between stained markers were analyzed using confocal microscopy (Zeiss LCM 800). To analyze the number of p-tau217-positive NFT and clusters with granulovacuolar degeneration bodies (GVB), three images ((3 × 0.15mm2) of the CA1 region was captured in two–three sections from each individual (in total 6–9 pictures) using an Olympus AX70 light microscope with the 20 × objective. Only clusters containing more than 10 GVBs were included in the analysis. The GVB clusters and NFTs in each picture of CA1 were counted manually by a blinded observer. The numbers were then averaged and presented as mean numbers of p-tau217 positive NFT/mm2 and p-tau217 positive GVB/mm2.
Analysis of p-tau217 area fraction
Analysis of the p-tau217 immuno-stained area fraction in Cohort 1 and 2 was performed by acquiring three images (3 × 0.15mm2) of the CA1 (Cohort 1 and 2), EC, (ITG), and SFG region (Cohort 2). The 4 different brain areas were defined based on area-characteristic landmarks and pictures within each brain area were captured by randomly selecting an area in the blue channel (DAPI). Two–three sections from each individual (in total 6–9 pictures) were analyzed using imageJ and the averaged values are presented as mean OD Area fraction (%).
Analysis of p-tau217 levels in plasma
The concentrations of plasma p-tau217 (cohort 2) were measured using the Meso scale discovery (MSD) platform as previously described . In short, small-spot streptavidin-plates were blocked with PBS + 3% BSA + 2% PEG for 1 h in RT and then incubated with biotinylated IBA493 (diluted at 0.5 µg/ml in PBS + 0.1% BSA + 0.05% Tween 20 + 2% PEG) for 1 h in RT. The samples were diluted 1:2 in assay buffer (50 mM HEPES, 60 mM NaCl, 5 mM EDTA, 5 mM EGTA, 1% Triton X‐100, 1% MSD blocker A, 2% PEG) with the addition of heterophilic blocking reagent 1 (Scantibodies Inc) to a concentration of 200 μg/ml. Diluted samples were thereafter added to the wells in duplicates and left for incubation for 2 h at RT, followed by incubation with SULFO-tagged 4G10‐E2 detection antibody (diluted in the assay buffer) for and an additional 1 h in RT. The plate was read on MSD SQ120 within 5 min after the addition of 2 × MSD Read Buffer. All plate incubations were performed with shaking on a plate shaker. The lower limit of detection of the plasma P-tau217 assay was 0.48 pg/mL. Plasma p-tau217 values below the lower detection limit (14%) of the assay were imputed to the lowest interpolated value.
Statistical analysis was performed using SPSS software (version 24 for Mac, SPSS Inc., Chicago, IL). Normal distribution was analyzed using Kolmogorov–Smirnov test. Differences between groups in Cohort 1 and Cohort 2 were analyzed using Kruskal Wallis Test corrected for Benjamini–Hochberg False discovery rate (FDR). Mann–Whitney Test was used when analyzing differences between two groups in Cohort 2. Correlation analysis was performed by Spearman correlation test. Results are presented as means ± standard deviations, and a value of p < 0.05 was considered statistically significant.
Cellular localization of p-tau217
To investigate the cellular localization of p-tau217 in relation to other markers, we immunostained hippocampal sections from AD patients and analyzed the CA1, a brain area known to show early tau pathology in AD. The p-tau217 staining yielded classical NFT and NT, but also clusters of vesicle-like structures (Fig. 1). Co-staining showed that tangles positive for p-tau217 were also positive for p-tau 181, 231, 202/205, 202, and 369/404 (Fig. 1A, D, G, J, M, respectively), but a few NFTs positive for tau, p-tau 369/404 and p-FTAA were not positive for p-tau217 (Additional file 1: Figure S1). Similarly, most NTs positive for p-tau217 were also positive for the five other p-tau variants (Fig. 1B, E, H, K, N). Importantly, staining against p-tau217 also yielded extensive vesicle-like patterns. Although a few of these p-tau217 positive vesicles were associated with vesicles positive for p-tau181, 231, 202/205, and 369/404 (indicated by the long arrow in Fig. 1C, F, I, O, respectively), most p-tau217 positive vesicles did not (indicated by the short arrow in Fig. 1C, F, I, L, O). The vesicle-like pattern also did not associate with markers against astrocytes or microglia (Additional file 1: Figure S1). The p-tau217 positive vesicles had a diameter ranging between 0.30 and 4.13 µm, which corresponds to large endosomes such as multivesicular bodies (MVB) . Indeed, a co-staining against p-tau217 and the MVB marker CD63 showed a strong association between the two markers (Fig. 2A). Moreover, since the vesicles were distributed in a pattern resembling granulovacuolar degeneration bodies (GVB), we also stained against p-tau217 together with the GVB marker Ckid . This staining showed that the majority of the p-tau217 positive vesicles were also positive for Ckid (Fig. 2B) and since they, in similarity to GVBs, were found in a much higher degree in CA1 compared to for example EC (Additional file 2: Figure S2), we will hereafter call these structures GVB. Co-labelling p-tau217 together with p-FTAA further showed that p-tau217 positive tangles were positive for p-FTAA, but none of the p-tau217 positive vesicles were associated with p-FTAA (Fig. 2C).
Presence of brain p-tau217 in neuropathological evaluated individuals in Cohort 1
Next, we investigated whether the amount of p-tau217 positive structures i.e. NFTs, NTs, and GVBs, corresponds to the overall neuropathological evaluation of NFTs and Aβ plaques in Cohort 1. The individuals where grouped based on diagnosis (non-demented controls (NC) and AD patients) and neuropathological evaluation (presence of NFT and Aβ) into 4 groups: NC−Aβ (NFT Braak stage I-II, Aβ Braak O), NC+Aβ (NFT Braak stage I-II, Aβ Braak A-B)), moderate AD (NFT Braak stage III-IV, Aβ Braak A-B) and severe AD (NFT Braak stage V-VI, Aβ Braak C). The area fraction of p-tau217 in pictures captured from the CA1 (Fig. 3A) was significantly higher in severe AD compared to NC−Aβ (p = 0.0008) and NC + Aβ (p = 0.0007) and in moderate AD compared to NC−Aβ (p = 0.030) and NC+Aβ (p = 0.027) (Fig. 3B–F). Number of p-tau217 NFTs was also significantly higher in severe AD compared to NC−Aβ (p = 0.0002) and NC+Aβ (p = 0.001) (Fig. 3G, H). Finally, severe AD and moderate AD showed a higher number of p-tau217 GVBs compared to NC+Aβ (p = 0.0005 and p = 0.020, respectively) and the same were higher in severe AD compared to NC−Aβ (p = 0.001) (Fig. 3H). No correlation was found between the number of NFTs and GVBs when the two AD groups were analyzed together, but when analyzed separately the number of NFTs in moderate AD increased (albeit not significantly) along with the number of GVBs (r = 0.700, p = 0.188), whereas the opposite was seen in severe AD (Fig. 3I).
Presence of brain p-tau217 in neuropathologically evaluated individuals in Cohort 2
To further investigate whether the amount of p-tau217 in the brain is related to diagnosis, we analyzed the area fraction of p-tau217 in individuals of Cohort 2, which contained patients with PART, non-AD tauopathies, intermediate AD, and high AD. Four representative brain areas of each individual (number of analyzed individuals of each brain area is indicated in brackets) were analyzed: EC (n = 39), CA1 (n = 41), ITG (n = 29), and SFG (n = 12). Analysis showed that the area fraction of p-tau217 was significantly higher in high AD compared to PART in EC (p = 0.008), CA1 (p = 0.007), and ITG (p = 0.00008) (representative images of p-tau217 area fraction in CA1 is found in Fig. 4A–D). The p-tau217 area fraction was also significantly higher in high AD compared to non-AD tauopathies in CA1 (p = 0.016), and in ITG (p = 0.021) as well as higher in ITG of high AD compared to intermediate AD (p = 0.005). Further, high AD also displayed significantly higher area fraction of p-tau 217 compared to PART (p = 0.0008), non-AD tauopathies (p = 0.004) and intermediate AD (p = 0.018) when the mean values of EC, CA1, and ITG (M1; n = 27) were analyzed (Fig. 4E). The individuals, in which also SFG was analyzed, were grouped into high AD (n = 7) and non-AD (n = 5), and analysis showed that the p-tau217 area fraction was significantly higher in high AD compared to non-AD (p = 0.048). Additionally, the mean value of p-tau217 area fraction in EC, CA1, ITG, and SFG (M2; n = 9) were significantly higher in high AD compared to non-AD (Fig. 4F).
Relations between brain and plasma p-tau217 in Cohort 2 individuals
To further investigate whether brain p-tau217 corresponds to levels of p-tau217 in plasma, we measured p-tau217 in antemortem collected plasma from the individuals in Cohort 2. The levels of plasma p-tau217 were significantly higher in high AD compared to PART (12.14 ± 5.72 vs 0.47 ± 0.48, p = 0.0000007, fold change 25.77), non-AD tauopathies (12.14 ± 5.72 vs 2.06 ± 0.93, p = 0.037, fold change 5.89) and intermediate AD (12.14 ± 5.72 vs 3.76 ± 2.50, p = 0.042, fold change 3.22). The latter was also significantly higher compared to PART (p = 0.008) (Fig. 4G). Subsequent correlation analysis of the whole cohort showed significant correlations between plasma p-tau217 and p-tau217 area fraction in all analyzed areas i.e. EC (r = 0,591, p = 0.000076), CA1 (r = 0.591, p = 0.000046), ITG (r = 0.791, p = 0.0000003) and SFG (r = 0.748, p = 0.005) as well as in M1 (r = 0.791, p = 0.0000009) and M2 (r = 0.900, p = 0.0009). When further analyzing the cohort based on the presence of amyloid plaque, we noted that the correlations in all analyzed areas were no longer significant in amyloid plaque negative individuals (p > 0.05) (Additional file 3: Figure S3), but remained significant in EC, CA1, ITG, SFG, and M1 of amyloid plaque positive individuals (Fig. 4H, I, J, K, L).
Correlation analysis of p-tau217 area fraction and load of Amyloid plaque and NFT/N8 in Cohort 2
Finally, we investigated whether the p-tau217 area fraction in the different brain areas was related to the amyloid plaque load or NFT/NT load. The area fraction of p-tau217 in all 4 areas correlated with amyloid plaque load and NFT/NT load within each area (bold in Table 4), but also with both load types in most of the other analyzed areas (Table 4). EC, CA1, ITG, M1, and M2 correlated also with total amyloid plaque load and NFT/NT load, whereas SFG only correlated with total NFT/NT load (Table 4).
Our study shows that p-tau217 can be found within NFTs and NTs also containing the p-tau variants p-tau181, 231, 202, 202/205, and 369/404, a finding suggesting that phosphorylation of tau at site Thr217 often occurs at the same time as phosphorylation at other tau sites. This idea is supported, not only by previous studies demonstrating strong correlations between levels of p-tau217 and various p-tau variants in plasma and CSF [4, 10, 11, 19, 20] but also by a recently published study showing that p-tau217 can be found in the same early tangle maturation stages as many of the other p-tau variants including p-tau181, 231, 205 . Our study adds to these studies by demonstrating subtle differences in the coverage of p-tau217 immunoreactivity in NFT and NT compared to the other p-tau variants. We also noted that a few tangles positive for tau, P-tau202, p-FTAA did not show p-tau217 immunoreactivity, and we thus conclude that although p-tau variants may arise at the same time during tangle maturation, they appear to accumulate in different compartments in the neurons. The most interesting finding was the persistent p-tau217 staining of vesicle-like structures in the CA1 region, something that was not seen to the same extent after staining for P-tau181, 231, 202, 202/205, and 369/404. The p-tau217 vesicle was associated with Ckid, which has been shown to efficiently distinguish intracellular GVB . These structures are defined as large membrane-bound vacuoles containing aggregated proteins including p-tau , TDP-43 , and Aβ . The GVBs are commonly seen in patients with tauopathies and are highly correlated with the spreading of tau pathology, in a stereotypical pattern from the entorhinal cortex to the neocortex, hypothalamus, amygdala, and eventually frontal and parietal cortex [21, 26]. Although found throughout the brain, GVBs are most frequently seen in CA1 neurons of AD patients . In line with these observations, the Ckid + / p-tau217 + found in our study was most prominent in the CA1 region, but also detected in the EC, albeit in general with a smaller number of vesicles in each cell. We found no p-tau217 + vesicle structures in the ITG or SFG. However, staining of these regions was performed only on samples from Cohort 2, which were formalin postfixed for a longer period compared to Cohort 1 and may thus yield weaker staining of these structures. The function of GVBs are still not fully understood but an increasing number of studies suggest a role within autophagy, where GVB co-labeled with late (and not early) autophagy markers  accumulate waste awaiting intracellular degradation . The formation of GVB has also been associated with necroptosis, a programmed form of neuronal necrosis characterized by the formation of necrosomes . These necrosomes, which correlate in numbers with both neuronal cell loss and NFT in AD patients, co-localize with the GVB marker Ckid in CA1 . Interestingly, recent studies have also found evidence pointing towards a role for GVBs in exosomal secretion, where the waist instead of being degraded is extracellularly secreted . Our observed association between p-tau217 vesicles and CD63 supports this idea since this glycoprotein is a well-known marker for MVB and secreted exosomes . Interestingly, seeding of tau in mice enhances the formation of GVB  and it has been suggested that GVB-bearing neurons show similarities to neurons in the early pre-tangles stage of tau pathology . Given these findings we hypothesize that the spreading of p-tau217 through the brain can be driven by GVB formation, leading to an early and efficient secretion and propagation of the p-tau217.
One of the goals of the present study was to investigate whether the brain load of p-tau217 is related to diagnosis. For that, we analyzed 4 representative brain areas (EC, CA1, ITG, and SFG) of individuals with PART, non-AD tauopathies, an intermediate likelihood of AD, and a high likelihood of AD. Since all individuals included in the study showed tauopathy within Braak stages III-V, it was interesting to find that individuals with high likelihood of AD showed significantly higher p-tau217 area fraction compared to both PART and non-AD tauopathies. It thus appears as if phosphorylation of tau at Thr217 is an event that is somewhat selective for AD-pathology. Of note, individuals with an intermediate likelihood of AD (who just like those with a high likelihood of AD show Aβ pathology) did not significantly differ from any of the other groups suggesting that Aβ pathology can be present without significantly altered phosphorylation of tau at Thr217 in the brain.
Finally, we investigated whether plasma levels of p-tau217 reflect the load of p-tau217 in the brain. Indeed, plasma p-tau217 levels correlated with the p-tau217 area fraction in all four brain areas. The correlations were only of moderate strength, which most probably is partly due to the fact that the area fraction is a rather crude quantitative method. But it is also important to point out that p-tau217 plasma levels most probably reflect the total load of p-tau217 load in the brain and not the amount of p-tau217 in single brain areas. To account for this limitation, we also calculated the mean value of the p-tau217 area fraction of the 4 analyzed brain regions (M2). Unfortunately, only 9 individuals had values from all 4 areas, and thus we also calculated the mean value of EC, CA, and ITG (M1). The correlation between p-tau217 plasma levels and p-tau217 area in M1 increased compared to when the areas were analyzed separately and became very strong when the same correlation with M2 (i.e. all 4 brain areas) was analyzed, highlighting the idea that p-tau217 plasma levels reflect an accumulation of p-tau217 throughout the cerebral cortex. Interestingly, when we divided Cohort 2 based on the presence of Aβ pathology, we noted that the correlation between plasma and brain p-tau217 only remained in individuals with amyloid plaque loads, and the correlations within each area were improved. This finding support previous studies demonstrating a relationship between p-tau217 and Aβ pathology [15, 16], and therefore we also investigated whether the p-tau217 area fraction in the different brain regions was related to amyloid plaque/Aβ pathology. Indeed, the area fraction of p-tau217 of each brain region correlated well with both amyloid plaque loads in the total and individual brain areas, again suggesting a link between Aβ pathology and phosphorylation of tau at site Thr217.
Our study has some additional limitations, besides the ones mentioned above. First of all, antibody specificity and affinity differ, and we cannot exclude that some of our association findings (or lack thereof) are affected by such limitations. Further, the area fraction of p-tau217 analysis was performed on 4 selected brain areas and we have can thus not fully grasp the association between plasma p-tau217 and the presence of p-tau217 in the whole brain. The brain area distribution of tau lesions in PSD and CBD follows a different pattern compared to AD , as tau lesions a more frequently found in the frontal area and less in the hippocampal areas in the former pathologies. These differences need to be taken into account when interpreting the results, but of note also SFG of the non-AD cases (which contained n = 3 PSP, n = 1 CBD, and n = 1 PART cases) displayed lowered p-tau217 area fraction compared to high AD. Also, a recent study has shown that PART is associated with an early specific presence of AT8 positive NFT and NTs in the CA2 and less of the same in the CA1, while the opposite is seen in AD cases . Such pathology-specific distribution pattern could affect our result, in particular the relationship between p-tau217 plasma levels and analysis of CA1, and may explain why the correlations are much improved when the values of all brain areas are summarized (M1 and M2). Finally, the number of individuals in different groups in Cohort 1 and Cohort 2 was rather small (ranging from 5 to 16), which may contribute to type 2 statistical errors. Hence, further studies on larger cohorts are warranted.
To conclude, our study, demonstrating the localization of p-tau217 in cellular structures specific for the p-tau variant, highlights differences between p-tau variants and invites further explorative studies aiming to understand the cellular pathways implicated in p-tau217 accumulation, seeding, and secretion. The found correlation found between p-tau217 plasma levels and p-tau217 brain load further supports the use of plasma p-tau217 as a biomarker to monitor AD pathology in future diagnostics.
Availability of data and material
All data generated or analysed during this study are included in this published article [and its supplementary information files].
(1997) Consensus recommendations for the postmortem diagnosis of Alzheimer’s disease. The National Institute on Aging, and Reagan Institute Working group on diagnostic criteria for the neuropathological assessment of Alzheimer’s disease. Neurobiol Aging 18:S1-2
Altick AL, Baryshnikova LM, Vu TQ, von Bartheld CS (2009) Quantitative analysis of multivesicular bodies (MVBs) in the hypoglossal nerve: evidence that neurotrophic factors do not use MVBs for retrograde axonal transport. J Comp Neurol 514:641–657. https://doi.org/10.1002/cne.22047
Aslund A, Sigurdson CJ, Klingstedt T, Grathwohl S, Bolmont T, Dickstein DL, Glimsdal E, Prokop S, Lindgren M, Konradsson P et al (2009) Novel pentameric thiophene derivatives for in vitro and in vivo optical imaging of a plethora of protein aggregates in cerebral amyloidoses. ACS Chem Biol 4:673–684. https://doi.org/10.1021/cb900112v
Barthelemy NR, Horie K, Sato C, Bateman RJ (2020) Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer’s disease. J Exp Med. https://doi.org/10.1084/jem.20200861
Barthelemy NR, Li Y, Joseph-Mathurin N, Gordon BA, Hassenstab J, Benzinger TLS, Buckles V, Fagan AM, Perrin RJ, Goate AM et al (2020) A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer’s disease. Nat Med 26:398–407. https://doi.org/10.1038/s41591-020-0781-z
Beach TG, Adler CH, Sue LI, Serrano G, Shill HA, Walker DG, Lue L, Roher AE, Dugger BN, Maarouf C et al (2015) Arizona study of aging and neurodegenerative disorders and brain and body donation program. Neuropathology 35:354–389. https://doi.org/10.1111/neup.12189
Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82:239–259
Funk KE, Mrak RE, Kuret J (2011) Granulovacuolar degeneration (GVD) bodies of Alzheimer’s disease (AD) resemble late-stage autophagic organelles. Neuropathol Appl Neurobiol 37:295–306. https://doi.org/10.1111/j.1365-2990.2010.01135.x
Hansson O (2021) Biomarkers for neurodegenerative diseases. Nat Med 27:954–963. https://doi.org/10.1038/s41591-021-01382-x
Janelidze S, Mattsson N, Palmqvist S, Smith R, Beach TG, Serrano GE, Chai X, Proctor NK, Eichenlaub U, Zetterberg H et al (2020) Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia. Nat Med 26:379–386. https://doi.org/10.1038/s41591-020-0755-1
Janelidze S, Stomrud E, Smith R, Palmqvist S, Mattsson N, Airey DC, Proctor NK, Chai X, Shcherbinin S, Sims JR et al (2020) Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer’s disease. Nat Commun 11:1683. https://doi.org/10.1038/s41467-020-15436-0
Koper MJ, Van Schoor E, Ospitalieri S, Vandenberghe R, Vandenbulcke M, von Arnim CAF, Tousseyn T, Balusu S, De Strooper B, Thal DR (2020) Necrosome complex detected in granulovacuolar degeneration is associated with neuronal loss in Alzheimer’s disease. Acta Neuropathol 139:463–484. https://doi.org/10.1007/s00401-019-02103-y
Kovacs GG, Lukic MJ, Irwin DJ, Arzberger T, Respondek G, Lee EB, Coughlin D, Giese A, Grossman M, Kurz C et al (2020) Distribution patterns of tau pathology in progressive supranuclear palsy. Acta Neuropathol 140:99–119. https://doi.org/10.1007/s00401-020-02158-2
Kumar S, Wirths O, Stuber K, Wunderlich P, Koch P, Theil S, Rezaei-Ghaleh N, Zweckstetter M, Bayer TA, Brustle O et al (2016) Phosphorylation of the amyloid beta-peptide at Ser26 stabilizes oligomeric assembly and increases neurotoxicity. Acta Neuropathol 131:525–537. https://doi.org/10.1007/s00401-016-1546-0
Mattsson-Carlgren N, Andersson E, Janelidze S, Ossenkoppele R, Insel P, Strandberg O, Zetterberg H, Rosen HJ, Rabinovici G, Chai X et al (2020) Abeta deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer’s disease. Sci Adv 6:eaaz2387. https://doi.org/10.1126/sciadv.aaz2387
Mattsson-Carlgren N, Janelidze S, Bateman RJ, Smith R, Stomrud E, Serrano GE, Reiman EM, Palmqvist S, Dage JL, Beach TG et al (2021) Soluble P-tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau. EMBO Mol Med 13:e14022. https://doi.org/10.15252/emmm.202114022
Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G, Berg L (1991) The consortium to establish a registry for Alzheimer’s disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer’s disease. Neurology 41:479–486. https://doi.org/10.1212/wnl.41.4.479
Moloney CM, Labuzan SA, Crook JE, Siddiqui H, Castanedes-Casey M, Lachner C, Petersen RC, Duara R, Graff-Radford NR, Dickson DW et al (2021) Phosphorylated tau fluid biomarker sites recognize earlier neurofibrillary tangle maturity levels in the postmortem Alzheimer’s disease brain. bioRxiv. https://doi.org/10.1101/2021.08.25.457363
Palmqvist S, Janelidze S, Quiroz YT, Zetterberg H, Lopera F, Stomrud E, Su Y, Chen Y, Serrano GE, Leuzy A et al (2020) Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA 324:772–781. https://doi.org/10.1001/jama.2020.12134
Suarez-Calvet M, Karikari TK, Ashton NJ, Lantero Rodriguez J, Mila-Aloma M, Gispert JD, Salvado G, Minguillon C, Fauria K, Shekari M et al (2020) Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer’s continuum when only subtle changes in Abeta pathology are detected. EMBO Mol Med 12:e12921. https://doi.org/10.15252/emmm.202012921
Thal DR, Del Tredici K, Ludolph AC, Hoozemans JJ, Rozemuller AJ, Braak H, Knippschild U (2011) Stages of granulovacuolar degeneration: their relation to Alzheimer’s disease and chronic stress response. Acta Neuropathol 122:577–589. https://doi.org/10.1007/s00401-011-0871-6
Thijssen EH, La Joie R, Wolf A, Strom A, Wang P, Iaccarino L, Bourakova V, Cobigo Y, Heuer H, Spina S et al (2020) Diagnostic value of plasma phosphorylated tau181 in Alzheimer’s disease and frontotemporal lobar degeneration. Nat Med 26:387–397. https://doi.org/10.1038/s41591-020-0762-2
Toh WS, Lai RC, Zhang B, Lim SK (2018) MSC exosome works through a protein-based mechanism of action. Biochem Soc Trans 46:843–853. https://doi.org/10.1042/BST20180079
Walker JM, Richardson TE, Farrell K, Iida MA, Foong C, Shang P, Attems J, Ayalon G, Beach TG, Bigio EH et al (2021) Early selective vulnerability of the CA2 hippocampal subfield in primary age-related tauopathy. J Neuropathol Exp Neurol 80:102–111. https://doi.org/10.1093/jnen/nlaa153
Wesseling H, Mair W, Kumar M, Schlaffner CN, Tang S, Beerepoot P, Fatou B, Guise AJ, Cheng L, Takeda S et al (2020) Tau PTM profiles identify patient heterogeneity and stages of Alzheimer’s disease. Cell 183(1699–1713):e1613. https://doi.org/10.1016/j.cell.2020.10.029
Wiersma VI, Hoozemans JJM, Scheper W (2020) Untangling the origin and function of granulovacuolar degeneration bodies in neurodegenerative proteinopathies. Acta Neuropathol Commun 8:153. https://doi.org/10.1186/s40478-020-00996-5
Wiersma VI, van Ziel AM, Vazquez-Sanchez S, Nolle A, Berenjeno-Correa E, Bonaterra-Pastra A, Clavaguera F, Tolnay M, Musters RJP, van Weering JRT et al (2019) Granulovacuolar degeneration bodies are neuron-selective lysosomal structures induced by intracellular tau pathology. Acta Neuropathol 138:943–970. https://doi.org/10.1007/s00401-019-02046-4
World Medical A (2013) World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 310:2191–2194. https://doi.org/10.1001/jama.2013.281053
Yamazaki Y, Matsubara T, Takahashi T, Kurashige T, Dohi E, Hiji M, Nagano Y, Yamawaki T, Matsumoto M (2011) Granulovacuolar degenerations appear in relation to hippocampal phosphorylated tau accumulation in various neurodegenerative disorders. PLoS ONE 6:e26996. https://doi.org/10.1371/journal.pone.0026996
Yamoah A, Tripathi P, Sechi A, Kohler C, Guo H, Chandrasekar A, Nolte KW, Wruck CJ, Katona I, Anink J et al (2020) Aggregates of RNA binding proteins and ER chaperones linked to exosomes in granulovacuolar degeneration of the Alzheimer’s disease brain. J Alzheimers Dis 75:139–156. https://doi.org/10.3233/JAD-190722
The authors thank Charlotte Nilsson and Emelie Henningsson for assisting labwork.
Open access funding provided by Lund University. This work was supported by the Swedish Research Council (2016-00906), Swedish Research Council (2018-02564) the Knut and Alice Wallenberg foundation (2017-0383), the Marianne and Marcus Wallenberg foundation (2015.0125), the Strategic Research Area MultiPark (Multidisciplinary Research in Parkinson’s disease) at Lund University, the Swedish Alzheimer Foundation (AF-939932), the Swedish Brain Foundation (FO2021-0293), The Parkinson foundation of Sweden (1280/20), the Skåne University Hospital Foundation (2020-O000028), Regionalt Forskningsstöd (2020-0314) and the Swedish federal government under the ALF agreement (2018-Projekt0279). The Arizona Study of Aging and Neurodegenerative Disorders and Brain and Body Donation Program has been supported by the National Institute of Neurological Disorders and Stroke (U24 NS072026) the National Institute on Aging (P30 AG19610, the Arizona Department of Health Services (contract 211002, Arizona Alzheimer’s Research Center), the Arizona Biomedical Research Commission (contracts 4001, 0011, 05–901 and 1001 to the Arizona Parkinson's Disease Consortium) and the Michael J. Fox Foundation for Parkinson’s Research. This work was also supported by Eli Lilly and Company through the Lilly Research Award Program (LRAP).
Ethics approval and consent to participate
The procedures of brain tissue and plasma collection and forms were approved, for Cohort 1, by the medical ethics committee of VU medical center in Amsterdam (the Netherlands), for Cohort 2 by the Western Institutional Review Board of Puyallup, Washington (USA), and for this study by the regional ethical review board in Lund.
Consent for publication
OH has acquired research support (for the institution) from AVID Radiopharmaceuticals, Biogen, Eli Lilly, Eisai, GE Healthcare, Pfizer, and Roche. In the past 2 years, he has received consultancy/speaker fees from Roche, Genentech, Siemens, Biogen, Alzpath, and Cerveau.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
. Immunostaining against P-tau217 and GFAP, Iba-1, tau, p-tau 369/404 and p-FTAA. Image in (A and B) show that neither GFAP positive astrocytes (asterisks in A) nor iba-1 positive microglia (asterisks in B) is assocaited with P-tau217 positive vesicles (arrows in A and B). Images in (C-E) show that not all tangles positive for tau (C) and p-tau396/404 (D), p-FTAA (E) Scalebar = 20 µm
. Immunostaining against Ckid. Image in (A and B) show pictures of Cornu Ammonus 1 (CA1) and entorhinal cortex (EC) of and AD patients captured with 20 × magnification. The number of Ckid positive clusters and vesicle within each cluster (indicated with arrows) are several times higher in CA1 (A) compared to EC (B). Scalebar = 20 µm
. Correlation analysis between p-tau217 plasma and p-tau217 area fraction in amyloid beta negative individuals. Scatter plotts in (A-F) show how p-tau217 plasma values relates to p-tau 217 area fraction in the Entorhinal cortex (EC) (A), Cornu Ammonium 1 (CA1) (B), inferior temporal gyrus (ITG) (C), superior frontal gyrus (SFG) (D), mean value of EC, CA1 and ITG (M1) (E) and mean value of EC, CA1, ITG and SFG (M2) (F) of amyloid beta negative individuals. Each point in (A-F) represents a mean of 3 pictures from 2–3 sections (in total 6–9) from each individual and data was analyzed using Spearman correlations test.
About this article
Cite this article
Wennström, M., Janelidze, S., Nilsson, K.P.R. et al. Cellular localization of p-tau217 in brain and its association with p-tau217 plasma levels. acta neuropathol commun 10, 3 (2022). https://doi.org/10.1186/s40478-021-01307-2
- Alzheimer’s disease